14.66

1.95% 0.28

After Hours: 14.34 -0.32 -2.18%

Trevi Therapeutics Inc (TRVI)

Overview News Price History Option Chain Financials Discussions Forecast

Trevi Therapeutics Inc stock is traded at $14.66, with a volume of 1.02M. It is up +1.95% in the last 24 hours and up +22.78% over the past month. Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

Previous Close:

$14.38

Open:

$14.49

24h Volume:

1.02M

Relative Volume:

0.69

Market Cap:

$2.08B

Revenue:

Net Income/Loss:

$-42.76M

P/E Ratio:

-45.70

EPS:

-0.3208

Net Cash Flow:

$-42.09M

1W Performance:

+5.92%

1M Performance:

+22.78%

6M Performance:

+37.78%

1Y Performance:

+112.46%

1-Day Range:

$14.28

$14.78

1-Week Range:

$13.11

$14.78

52-Week Range:

$5.3801

$16.12

Trevi Therapeutics Inc Stock (TRVI) Company Profile

Name

Trevi Therapeutics Inc

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

203-304-2499

Address

195 CHURCH STREET, NEW HAVEN, CT

Employee

Twitter

@TreviThera

Next Earnings Date

2026-05-05

Latest SEC Filings

TRVI's Discussions on Twitter

Compare TRVI vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TRVI Trevi Therapeutics Inc	14.66	2.04B	0	-42.76M	-42.09M	-0.3208
VRTX Vertex Pharmaceuticals Inc	424.36	109.34B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.02B	5.36B	287.73M	924.18M	2.5229

Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-13-25	Initiated	Leerink Partners	Outperform
Aug-21-25	Initiated	Morgan Stanley	Overweight
Jul-01-25	Initiated	Cantor Fitzgerald	Overweight
May-28-25	Initiated	H.C. Wainwright	Buy
Mar-10-25	Reiterated	Needham	Buy
Mar-10-25	Upgrade	Raymond James	Outperform → Strong Buy
Dec-12-24	Reiterated	H.C. Wainwright	Buy
Sep-09-24	Resumed	Leerink Partners	Outperform
Aug-30-24	Initiated	H.C. Wainwright	Buy
Aug-30-24	Initiated	Raymond James	Outperform
Jun-13-24	Initiated	Rodman & Renshaw	Buy
Apr-12-23	Initiated	B. Riley Securities	Buy
Nov-22-22	Initiated	SVB Leerink	Outperform
Jun-03-19	Initiated	BMO Capital Markets	Outperform
Jun-03-19	Initiated	Needham	Buy
Jun-03-19	Initiated	SVB Leerink	Outperform
Jun-03-19	Initiated	Stifel	Buy

View All

Trevi Therapeutics Inc Stock (TRVI) Latest News

05:20 AM

Trevi Therapeutics Q1 2026 Earnings Call Transcript - Benzinga

05:20 AM

05:18 AM

Earnings call transcript: Trevi Therapeutics Q1 2026 highlights cash boost and clinical progress - Investing.com Canada

05:18 AM

04:31 AM

Trevi Therapeutics (NASDAQ:TRVI) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat

04:31 AM

04:17 AM

Trevi Therapeutics (NASDAQ: TRVI) raises $162M, funds cough trials - Stock Titan

04:17 AM

04:09 AM

Trevi Therapeutics (NASDAQ: TRVI) widens Q1 loss and raises $173M - Stock Titan

04:09 AM

Fresh $162M gives Trevi runway into 2030 ahead of Phase 3 cough trials - Stock Titan

04:09 AM

04:05 AM

Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates - GlobeNewswire

04:05 AM

02:06 AM

MSN Money - MSN

02:06 AM

May 02, 2026

Pictet Asset Management Holding SA Purchases 1,520,754 Shares of Trevi Therapeutics, Inc. $TRVI - MarketBeat

May 02, 2026

Apr 30, 2026

Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference - The Manila Times

Apr 30, 2026

Trevi Therapeutics, Inc. Announces Oral Nalbuphine Extended-Release Clinical Trial Results And Presentations - marketscreener.com

Apr 30, 2026

Trevi Therapeutics (TRVI) Expected to Announce Quarterly Earnings on Thursday - MarketBeat

Apr 30, 2026

Apr 29, 2026

Trevi Therapeutics (TRVI.US) is scheduled to release its earnings report after the market closes on May 5. - Moomoo

Apr 29, 2026

TRVI stock’s five-day rally pushes it to an all-time high – here’s what’s happening - MSN

Apr 29, 2026

Trevi Therapeutics Closes $173 Million Public Offering - Global Legal Chronicle

Apr 29, 2026

Apr 28, 2026

Clinical-stage biotech Trevi sets May 5 webcast for Q1 results - Stock Titan

Apr 28, 2026

Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026 - marketscreener.com

Apr 28, 2026

Apr 27, 2026

Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024 - Quantisnow

Apr 27, 2026

Trevi Therapeutics launches $150M public stock offering - MSN

Apr 27, 2026

Apr 24, 2026

Peregrine Capital Management LLC Lowers Stake in Trevi Therapeutics, Inc. $TRVI - MarketBeat

Apr 24, 2026

Trevi Therapeutics to Participate in Upcoming May Events - The Manila Times

Apr 24, 2026

Apr 23, 2026

New Haven-based Trevi Therapeutics raises $173M in public offering - Hartford Business Journal

Apr 23, 2026

Trevi lines up a May 7 investor day and May 12 conference webcast - Stock Titan

Apr 23, 2026

Apr 22, 2026

Trevi Therapeutics (TRVI) Stock: Is It Holding Support | Q4 2025: Earnings Beat EstimatesEquity Raise - Cổng thông tin điện tử Tỉnh Sơn La

Apr 22, 2026

Did Trevi’s US$173 Million Raise and Share Expansion Just Reshape Trevi Therapeutics' (TRVI) Investment Narrative? - Yahoo Finance

Apr 22, 2026

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat

Apr 22, 2026

Apr 21, 2026

Trevi Therapeutics (NASDAQ: TRVI) asks holders to OK share, equity plan boosts - Stock Titan

Apr 21, 2026

[ARS] Trevi Therapeutics, Inc. SEC Filing - Stock Titan

Apr 21, 2026

Leerink raises Trevi Therapeutics stock price target on ILD outlook By Investing.com - Investing.com Canada

Apr 21, 2026

Apr 20, 2026

Trevi Therapeutics Closes $173 Million Share Offering - marketscreener.com

Apr 20, 2026

Trevi Therapeutics announces closing of $173 million underwritten offering - marketscreener.com

Apr 20, 2026

Trevi Therapeutics Announces Closing Of $173 Million Underwritten Offering - TradingView

Apr 20, 2026

Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares - ChartMill

Apr 20, 2026

Can Trevi Therapeutics Address The Big Unmet Need In Chronic Cough? - RTTNews

Apr 20, 2026

Apr 18, 2026

Trevi Therapeutics (TRVI) Stock: Slowing Down? (Breakout Watch) 2026-04-18Trending Picks - Cổng thông tin điện tử tỉnh Tây Ninh

Apr 18, 2026

What's Going On With Trevi Therapeutics Stock? - Sahm

Apr 18, 2026

Netflix, Trevi Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Sahm

Apr 18, 2026

Apr 17, 2026

TRVI Maintains Buy Rating by D. Boral Capital -- Price Target Un - GuruFocus

Apr 17, 2026